Abstract 229P
Background
Fatigue is a common adverse effect suffered by prostate cancer patients receiving androgen deprivation therapy (ADT). A growing body of evidence has proposed exercise as a treatment to relieve and prevent the adverse effects of ADT. Recently, high-quality randomized controlled trials (RCTs) of supervised exercise have been conducted to get more assessment. However, the pooled estimate for the effect of supervised exercise on fatigue has not been established yet. This study aims to determine the pooled effect of supervised exercise on fatigue in prostate cancer patients receiving ADT.
Methods
A literature search was conducted from PubMed, Clinicaltrial, and Cochrane Library, published up to January 2020 following the PRISMA guideline. We screened RCTs with our inclusion criteria and assessed the quality using the tools provided by Cochrane. The primary outcome analyzed in this study was fatigue measured as Standardized Mean Difference (SMD) with 95% Confidence Intervals (CIs). Heterogeneity was assessed using the I2 test. Subgroup analysis was conducted to determine the difference in exercise duration (<12 weeks and >12 weeks), modality (aerobic, resistance, and combination), and the onset of ADT (initiation and long-term). All analysis was performed using STATA 16.
Results
A total of 7 RCTs comprising 455 patients reported the fatigue using the FACIT-Fatigue, EORTC QLQ-C30, and Schwartz Cancer Fatigue Scale. The included studies presented a low risk of bias. Supervised exercise showed an overall reduction on fatigue (SMD = 0.25, 95%CI 0.07-0.44, p = 0.01, I2 = 0%). The subgroup test results showed no significant difference between exercise duration (p = 0.4), modality (p = 0.67), and onset of ADT (p = 0.57). The Egger’s test results showed no indication of publication bias (p = 0.64).
Conclusions
Supervised exercise reduces fatigue in prostate cancer patients receiving ADT. The available data show that there is no difference between exercise duration and modality. Furthermore, our findings highlight the benefits of supervised exercise in the initiation of ADT for preventing toxicities as well as relieving adverse effects in long-term ADT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session